Kurzfassung

A phase II, double-blind, placebo-controlled randomized study evaluating the safety and efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in patients with previously untreated advanced or recurrent non-small cell lung cancer